We have succeeded in immortalizing human lymphocytes derived from the peripheral blood of a healthy donor and of an atopic patient, and from the lymph node of a cancer patient by oncogene transfection (Alam et al., 1996) .
Introduction
In comparison with rodent-derived cells, the immortalization of human-derived cells has been shown to be very difficult. Several methods to immortalize human T cells have been reported, such as 1) treatment of carcinogens (Russo et al., 1988) , 2) irradiation of UV light or X-rays (Borek et al., 1980) , 3) transfection with SV40 large T antigen (Shay et al., 1989), 4) infection with specific viruses such as Epstein-Barr virus (Stevenson et al., 1986) and Herpesvirus saimiri (Troidl et al., 1994) , and 5) stimulation with specific antigens in the presence of the antigen presenting cells (van Neerven et al., 1993) . However, establishment of functional human cells with the ability to overcome crisis and to acquire immortality still remains quite difficult. We have succeeded in establishing a novel method to effectively and reproducibly immortal-ize human lymphocytes by the oncogene transfection (Alam et al., 1996) . Here, we characterized immortalized human lymphocytes derived from the peripheral blood of a healthy donor and an atopic patient, and from the lymph node of a cancer patient, and investigated whether the functional properties of these immortalized T cells are maintained after immortalization. We then further evaluated the phenotypical differences of these immortalized T cells with respect to their origin.
Materials and methods

Transfection of oncogenes into human lymphocytes
Five oncogenes (human c-Ha-ras, human c-myc, human c-fos, avian v-jun and avian v-myb) were used for immortalizing human lymphocytes. The oncogene expression plasmids were constructed by inserting each oncogene downstream from the human cytomegalovirus promoter in pRc/CMV vector (Invitrogen, San Diego, CA, U.S.A.) as described elsewhere (Yano et al., 1994) . Transfection methods used to introduce the oncogene expression plasmids into the human lymphocytes and maintenance of these transfected lymphocytes have been described elsewhere (Alam et al., 1996) . Transfection with a single oncogene was previously shown to be not effective for immortalizing human lymphocytes (Okano et al., 1993) . Therefore, we randomly selected two oncogenes out of five for simultaneous transfection. Oncogenes were introduced into lymphocytes using the electroporation method (Okano et al., 1993) . Transfected human lymphocytes were maintained in the ERDF medium (Kyokuto Pharmaceutical Co., Tokyo, Japan) containing 10% fetal bovine serum (FBS; Irvine Scientific, Santa Ana, CA, U.S.A.), 1.5 l ml 1 of bone marrow extract (Alam et al., 1996) , 1.0 l ml 1 of egg yolk lipoprotein (Murakami et al., 1988) , 5 g ml 1 of insulin (Novo Nordisk, Tokyo, Japan), 20 g ml 1 of transferrin, 20 mM of ethanolamine, 25 nM of sodium selenite and 20 U ml 1 of human interleukin 2 (hIL-2; Genzyme, Cambridge, MA, U.S.A.) at 37 C under humidified 5% CO 2 and 95% air atmosphere. Cloning of immortalized human lymphocytes is being continued. The data included in all figures and tables in this study show the results obtained by using the mixed clone cultures immortalized upon the transfection of the shown oncogene combination. 
Flowcytometry analysis
Proliferative responses of immortalized T cells
Proliferative responses of immortalized T cells in the presence of concanavalin A (Con A) and hIL-2 were assessed by WST-1 assay (Dojindo, Kumamoto, Japan) according to the manufacturer's manual. Briefly, the immortalized T cells were stimulated with 10 g ml 1 of Con A in the presence of 10 U ml 1 of hIL-2 in 96-well plates and kept for 8 days at 37 C in a humidified 5% CO 2 incubator. Twenty l of WST-1 dye solution (65 mg WST-1 (Dojindo) and 7 mg of 1-methoxy PMS (Dojindo) in 100 ml phosphate-buffered saline (PBS)) was then directly added to the culture. After the incubation for 4 h, the absorbance at 450 nm was measured.
Cytokine production of immortalized T cells
Total RNA was prepared by TRIzol reagent (LIFE TECHNOLOGIES, Gaitherburg, MD, U.S.A.) from human peripheral blood lymphocytes and immortalized T cells, both of which were stimulated with 5 g ml 1 of phytohemagglutinin (PHA) and 5 g ml 1 of Con A for 10 h. Five g of total RNA was reversetranscribed with AMV-reverse transcriptase (WAKO, Osaka, Japan) using d(T) 12 18 primer. One g of the resulting synthesized cDNA was used as template for PCR with Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN, U.S.A.). PCR was initiated at 94 C for 2 min, followed by 30 cycles of 30 sec at 94 C, 30 sec at 55 C, and 1 min at 72 C. Proliferative responses were assessed by WST-1 assay as described above. The stimulation index (SI) was calculated as the mean absorbance in the presence of stimulator cells divided by the mean absorbance in the absence of stimulator cells.
Results and discussions
Human lymphocytes immortalized by oncogene transfection
As shown in Table 1 , 317, 154 and 692 individual immortalized human lymphocyte cell lines were established by oncogene transfection of the lymphocytes derived from the healthy donor, the atopic patient and the cancer patient respectively, demonstrating that our oncogene transfection method is effective and reproducible for the immortalization of human lymphocytes. These immortalized lymphocytes could be indefinitely propagated independent of the need for antigen and/or Table 2 shows that the immortalized human lymphocytes, regardless where they were derived from, were all CD3 + and CD19 , indicating that these immortalized human lymphocytes were all T cells. The ratios of CD4 + and CD8 + subsets within the population of immortalized T cells derived from the healthy donor does not reflect the profile for the primary lymphocytes, rather they were shown to be variable dependant upon the oncogene they were transfected with (Table 2) . Especially, healthy donor derived immortalized T cells resulting from transfection with the c-Haras and v-jun combination were demonstrated to be only CD4 + T cells. On the other hand, immortalized T cells derived from either the atopic patient or the cancer patient were shown to be dominantly CD8 + regardless of which oncogene combination they were transfected with. CD8 + dominancy was also seen in primary cells Relative amounts of human lymphocytes with specific surface marker antigens were evaluated by flowcytometry analysis and the results are shown as follows: +++ = >70%; ++ = 2070%; + = <20%; -= Not detected.
Surface marker antigens on immortalized human lymphocytes
taken from the cancer patient. These results indicate that the CD4 + and CD8 + ratios of immortalized T cells derived from the cancer patient may reflect the T cell ratio in primary culture.
Furthermore, analysis of surface expression of the IL-2 receptor (IL-2R) demonstrated that IL-2R + T cell subpopulations could be detected only in the immortalized T cells derived from the cancer patient (Table 2) . These results could explain the IL-2- dependent proliferation of the immortalized T cells derived from the cancer patient as discussed below.
Proliferative responses of immortalized T cells
Proliferative responses of immortalized T cells in the absence or presence of hIL-2 were assessed by WST-1 assay (Fig. 1) . Proliferative responses of these immortalized T cells against exogenous hIL-2 were varied, depending upon their origins. Immortalized T cells derived from the healthy donor showed vigorous propagation both in the absence and presence of exogenous hIL-2. However, immortalized T cells derived from the cancer patient showed high responses only in the presence of exogenous hIL-2. The IL-2-dependent proliferative responses of the cancer patient derived immortalized T cells are consistent with their surface expression of IL-2R, and might be related to the high expression of CD8 antigen. The CD8 + T cells are thought not to be able to produce sufficient IL-2 for self proliferation (Schwartz et al., 1992) , but can proliferate in response to increased concentrations of IL-2 or the presence of other cytokines (Zupo et al., 1993) . The requirement of exogenous hIL-2 for the spontaneous growth of these immortalized T cells suggest that these cells retain the phenotypical function of the primary CD8 + T cells which exhibit cytokinedependent growth (Karasuyama et al., 1989) . This IL-2-dependency of immortalized T cells derived from the cancer patient might explain their high immortalization efficiency, because oncogene transfected lymphocytes were cultured in the presence of exogenous hIL-2 until they were shown to be immortalized. On the other hand, the immortalized T cells derived from the atopic patient showed low responses both in the absence and presence of exogenous hIL-2. These results suggest that the immortalized T cells were in different subsets or in different activated states depending upon their origins when immortalized. Primary T cells and immortalized T cells from the healthy donor showed a slightly higher response in the presence of exogenous hIL-2 when compared to exogenous hIL-2 negative conditions, although individual immortalized T cell proliferative response varied depending upon the oncogene combination used. Interestingly, this oncogene combination dependent variance could not be observed in immortalized T cells derived from the cancer patient or from the atopic patient. These results suggest that the transfected oncogene combinations do not always influence the proliferative responses of immortalized T cells. 
Relative amount of each cytokine mRNA was assessed by the strength of the band corresponding to each PT-PCR product. +++ = Strong band similary as GAPD; ++ = thin but clear band; + = faint band; -= Not detected.
Cytokine secretion patterns for immortalized T cells
The cytokine production patterns of the immortalized T cells derived from the healthy donor and the cancer patient were investigated by RT-PCR (Table 3) . IL-2 mRNA from immortalized T cells derived from the healthy donor could be detected in 10 out of 11 oncogene combinations. IL-6 and IL-10 mRNAs were detected in 2 oncogene combinations. GM-CSF mRNA could also be detected in 5 oncogene combinations, and a higher amount of IFN-mRNA was detected in 5 oncogene combinations. The immortalized T cells transfected with the c-Ha-ras/v-myb and the v-jun/vmyb combinations produced 5 out of 6 cytokines tested. Immortalized T cells transfected with c-Ha-ras only or c-Ha-ras in combination with other oncogenes were shown to be high producers of cytokines as compared to other oncogene combinations. These results suggest that the oncogene products of c-Ha-ras and/or v-myb might function in the signaling network which is important for cytokine secretion.
Overall cytokine production of immortalized T cells derived from the cancer patient was very low as compared to those from the healthy donor. Indeed, although low amounts GM-CSF mRNA was detected in 5 out of 11 oncogene combinations, other cytokines tested could hardly be detected. This biased expression of the GM-CSF mRNA and the decreased expression of IL-2 and IFN-might have some relationship to the occurrence of cancer. In fact, Pisa et al. (1992) reported the selective expression of GM-CSF mRNA in ovarian tumor tissue as compared to normal ovaries. Furthermore, when stimulated with mitogens, the cancer patient derived immortalized T cells produced low levels of cytokines. These T cells however vigorously proliferated in response to the exogenous hIL-2. The fact that proliferative responses against mitogen does not correlate with cytokine production in the immortalized T cells derived from the cancer patient might have some relation to the fact that CD8 + T cells were the dominant subpopulation.
Mixed lymphocyte reactions of immortalized T cells
We examined the responses of oncogene-transfected T cells to allogenic or xenogenic stimulator cells (Fig. 2) . Immortalized T cells from the cancer patient responded preferentially to K562 cells, which were used as target cells in a natural killer assay. Furthermore, immortalized T cells from the healthy donor responded preferentially to K562, Jurkat and RAJI cells, but only slightly to Daudi cells. These results indicate that the immortalized T cells maintained the ability to recognize specific antigens. Furthermore, the immortalized T cells from both donors were shown to contain K562 responsive cells, suggesting that T cells having MHC-nonrestricted killer activity might be effectively immortalized using our procedure.
In 8 out of 11 oncogene combinations, proliferative responses of immortalized T cells from the healthy donor were shown to be higher than the immortalized T cells from the cancer patient, indicating that the immortalized T cells from the healthy donor have an increased reactivity to allogenic and xenogenic stimulator cells. The low responses against stimulator cells observed in the immortalized T cells derived from the cancer patient might be explained in part by the fact that these T cells are derived from a cancer patient whose immune system was generally considered to be suppressed and that CD8 + T cells were the dominant subpopulation. We speculate that the immortalized T cells derived from the cancer patient were generally unresponsive against stimulation with specific anti-gens, although these T cells maintained the ability to proliferate in the presence of hIL-2.
In this study, we demonstrated that by transfecting human lymphocytes with various oncogene combinations, we easily and reproducibly obtained immortalized functional human T cells. Infection of human lymphocytes with Herpesvirus saimiri (HVS) was also considered to be an effective method to immortalize human T cells (Biesinger et al. 1992) . However, the immortalized T cells obtained by the infection with HVS were reported to have a partially altered functionality as compared to the parental T cells (De Carli et al. 1993) . In this respect, we must further investigate whether our immortalized T cells maintain functions similar to the primary T cells. However, high immortalization efficiency demonstrated by our method can be used to establish novel functional human T cells for further understanding the immune system in vivo.
